<?xml version="1.0" encoding="utf-8"?>
<uniprot xmlns="http://uniprot.org/uniprot" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://uniprot.org/uniprot http://www.uniprot.org/support/docs/uniprot.xsd">
<entry dataset="Swiss-Prot" created="1990-08-01" modified="2020-10-07" version="219">
<accession>P16410</accession>
<accession>A0N1S0</accession>
<accession>E9PDH0</accession>
<accession>O95653</accession>
<accession>Q0PP65</accession>
<accession>Q52MC1</accession>
<accession>Q53TD5</accession>
<accession>Q5S005</accession>
<accession>Q8WXJ1</accession>
<accession>Q96P43</accession>
<accession>Q9UKN9</accession>
<name>CTLA4_HUMAN</name>
<protein>
<recommendedName>
<fullName>Cytotoxic T-lymphocyte protein 4</fullName>
</recommendedName>
<alternativeName>
<fullName>Cytotoxic T-lymphocyte-associated antigen 4</fullName>
<shortName>CTLA-4</shortName>
</alternativeName>
<cdAntigenName>CD152</cdAntigenName>
</protein>
<gene>
<name type="primary">CTLA4</name>
<name type="synonym">CD152</name>
</gene>
<organism>
<name type="scientific">Homo sapiens</name>
<name type="common">Human</name>
<dbReference type="NCBI Taxonomy" id="9606"/>
<lineage>
<taxon>Eukaryota</taxon>
<taxon>Metazoa</taxon>
<taxon>Chordata</taxon>
<taxon>Craniata</taxon>
<taxon>Vertebrata</taxon>
<taxon>Euteleostomi</taxon>
<taxon>Mammalia</taxon>
<taxon>Eutheria</taxon>
<taxon>Euarchontoglires</taxon>
<taxon>Primates</taxon>
<taxon>Haplorrhini</taxon>
<taxon>Catarrhini</taxon>
<taxon>Hominidae</taxon>
<taxon>Homo</taxon>
</lineage>
</organism>
<reference key="1">
<citation type="journal article" date="1991" name="J. Immunol." volume="147" first="1037" last="1044">
<title>CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location.</title>
<authorList>
<person name="Harper K."/>
<person name="Balzano C."/>
<person name="Rouvier E."/>
<person name="Mattei M.-G."/>
<person name="Luciani M.-F."/>
<person name="Golstein P."/>
</authorList>
<dbReference type="PubMed" id="1713603"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1)</scope>
<scope>TISSUE SPECIFICITY</scope>
<scope>ALTERNATIVE SPLICING</scope>
<scope>VARIANT ALA-17</scope>
</reference>
<reference key="2">
<citation type="journal article" date="2001" name="Genomics" volume="78" first="155" last="168">
<title>Assembly and annotation of human chromosome 2q33 sequence containing the CD28, CTLA4, and ICOS gene cluster: analysis by computational, comparative, and microarray approaches.</title>
<authorList>
<person name="Ling V."/>
<person name="Wu P.W."/>
<person name="Finnerty H.F."/>
<person name="Agostino M.J."/>
<person name="Graham J.R."/>
<person name="Chen S."/>
<person name="Jussiff J.M."/>
<person name="Fisk G.J."/>
<person name="Miller C.P."/>
<person name="Collins M."/>
</authorList>
<dbReference type="PubMed" id="11735222"/>
<dbReference type="DOI" id="10.1006/geno.2001.6655"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA]</scope>
</reference>
<reference key="3">
<citation type="journal article" date="2008" name="Clin. Immunol." volume="128" first="374" last="381">
<title>Identification of CTLA-4 isoforms produced by alternative splicing and their association with myasthenia gravis.</title>
<authorList>
<person name="Gu M."/>
<person name="Kakoulidou M."/>
<person name="Giscombe R."/>
<person name="Pirskanen R."/>
<person name="Lefvert A.K."/>
<person name="Klareskog L."/>
<person name="Wang X."/>
</authorList>
<dbReference type="PubMed" id="18595775"/>
<dbReference type="DOI" id="10.1016/j.clim.2008.05.006"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3 AND 4)</scope>
<scope>VARIANT ALA-17</scope>
<scope>ALTERNATIVE SPLICING</scope>
<scope>POLYMORPHISM</scope>
</reference>
<reference key="4">
<citation type="submission" date="2001-08" db="EMBL/GenBank/DDBJ databases">
<title>Full length sequence of hCTLA4 cDNA.</title>
<authorList>
<person name="Wu P.W."/>
<person name="Ling V."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1)</scope>
</reference>
<reference key="5">
<citation type="submission" date="2006-01" db="EMBL/GenBank/DDBJ databases">
<authorList>
<consortium name="NIEHS SNPs program"/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA]</scope>
</reference>
<reference key="6">
<citation type="journal article" date="2005" name="Nature" volume="434" first="724" last="731">
<title>Generation and annotation of the DNA sequences of human chromosomes 2 and 4.</title>
<authorList>
<person name="Hillier L.W."/>
<person name="Graves T.A."/>
<person name="Fulton R.S."/>
<person name="Fulton L.A."/>
<person name="Pepin K.H."/>
<person name="Minx P."/>
<person name="Wagner-McPherson C."/>
<person name="Layman D."/>
<person name="Wylie K."/>
<person name="Sekhon M."/>
<person name="Becker M.C."/>
<person name="Fewell G.A."/>
<person name="Delehaunty K.D."/>
<person name="Miner T.L."/>
<person name="Nash W.E."/>
<person name="Kremitzki C."/>
<person name="Oddy L."/>
<person name="Du H."/>
<person name="Sun H."/>
<person name="Bradshaw-Cordum H."/>
<person name="Ali J."/>
<person name="Carter J."/>
<person name="Cordes M."/>
<person name="Harris A."/>
<person name="Isak A."/>
<person name="van Brunt A."/>
<person name="Nguyen C."/>
<person name="Du F."/>
<person name="Courtney L."/>
<person name="Kalicki J."/>
<person name="Ozersky P."/>
<person name="Abbott S."/>
<person name="Armstrong J."/>
<person name="Belter E.A."/>
<person name="Caruso L."/>
<person name="Cedroni M."/>
<person name="Cotton M."/>
<person name="Davidson T."/>
<person name="Desai A."/>
<person name="Elliott G."/>
<person name="Erb T."/>
<person name="Fronick C."/>
<person name="Gaige T."/>
<person name="Haakenson W."/>
<person name="Haglund K."/>
<person name="Holmes A."/>
<person name="Harkins R."/>
<person name="Kim K."/>
<person name="Kruchowski S.S."/>
<person name="Strong C.M."/>
<person name="Grewal N."/>
<person name="Goyea E."/>
<person name="Hou S."/>
<person name="Levy A."/>
<person name="Martinka S."/>
<person name="Mead K."/>
<person name="McLellan M.D."/>
<person name="Meyer R."/>
<person name="Randall-Maher J."/>
<person name="Tomlinson C."/>
<person name="Dauphin-Kohlberg S."/>
<person name="Kozlowicz-Reilly A."/>
<person name="Shah N."/>
<person name="Swearengen-Shahid S."/>
<person name="Snider J."/>
<person name="Strong J.T."/>
<person name="Thompson J."/>
<person name="Yoakum M."/>
<person name="Leonard S."/>
<person name="Pearman C."/>
<person name="Trani L."/>
<person name="Radionenko M."/>
<person name="Waligorski J.E."/>
<person name="Wang C."/>
<person name="Rock S.M."/>
<person name="Tin-Wollam A.-M."/>
<person name="Maupin R."/>
<person name="Latreille P."/>
<person name="Wendl M.C."/>
<person name="Yang S.-P."/>
<person name="Pohl C."/>
<person name="Wallis J.W."/>
<person name="Spieth J."/>
<person name="Bieri T.A."/>
<person name="Berkowicz N."/>
<person name="Nelson J.O."/>
<person name="Osborne J."/>
<person name="Ding L."/>
<person name="Meyer R."/>
<person name="Sabo A."/>
<person name="Shotland Y."/>
<person name="Sinha P."/>
<person name="Wohldmann P.E."/>
<person name="Cook L.L."/>
<person name="Hickenbotham M.T."/>
<person name="Eldred J."/>
<person name="Williams D."/>
<person name="Jones T.A."/>
<person name="She X."/>
<person name="Ciccarelli F.D."/>
<person name="Izaurralde E."/>
<person name="Taylor J."/>
<person name="Schmutz J."/>
<person name="Myers R.M."/>
<person name="Cox D.R."/>
<person name="Huang X."/>
<person name="McPherson J.D."/>
<person name="Mardis E.R."/>
<person name="Clifton S.W."/>
<person name="Warren W.C."/>
<person name="Chinwalla A.T."/>
<person name="Eddy S.R."/>
<person name="Marra M.A."/>
<person name="Ovcharenko I."/>
<person name="Furey T.S."/>
<person name="Miller W."/>
<person name="Eichler E.E."/>
<person name="Bork P."/>
<person name="Suyama M."/>
<person name="Torrents D."/>
<person name="Waterston R.H."/>
<person name="Wilson R.K."/>
</authorList>
<dbReference type="PubMed" id="15815621"/>
<dbReference type="DOI" id="10.1038/nature03466"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]</scope>
</reference>
<reference key="7">
<citation type="journal article" date="2004" name="Genome Res." volume="14" first="2121" last="2127">
<title>The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).</title>
<authorList>
<consortium name="The MGC Project Team"/>
</authorList>
<dbReference type="PubMed" id="15489334"/>
<dbReference type="DOI" id="10.1101/gr.2596504"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1)</scope>
<source>
<tissue>Lung</tissue>
</source>
</reference>
<reference key="8">
<citation type="journal article" date="1988" name="Eur. J. Immunol." volume="18" first="1901" last="1905">
<title>Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains.</title>
<authorList>
<person name="Dariavach P."/>
<person name="Mattei M.-G."/>
<person name="Golstein P."/>
<person name="Lefranc M.-P."/>
</authorList>
<dbReference type="PubMed" id="3220103"/>
<dbReference type="DOI" id="10.1002/eji.1830181206"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-223</scope>
<source>
<tissue>Lymphocyte</tissue>
</source>
</reference>
<reference key="9">
<citation type="submission" date="1997-02" db="EMBL/GenBank/DDBJ databases">
<authorList>
<person name="Oaks M.K."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] OF 38-223 (ISOFORM 5)</scope>
<source>
<tissue>Lymph node</tissue>
</source>
</reference>
<reference key="10">
<citation type="journal article" date="1999" name="Genomics" volume="60" first="341" last="355">
<title>Complete sequence determination of the mouse and human CTLA4 gene loci: cross-species DNA sequence similarity beyond exon borders.</title>
<authorList>
<person name="Ling V."/>
<person name="Wu P.W."/>
<person name="Finnerty H.F."/>
<person name="Sharpe A.H."/>
<person name="Gray G.S."/>
<person name="Collins M."/>
</authorList>
<dbReference type="PubMed" id="10493833"/>
<dbReference type="DOI" id="10.1006/geno.1999.5930"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 140-223</scope>
<scope>TISSUE SPECIFICITY</scope>
</reference>
<reference key="11">
<citation type="journal article" date="1991" name="J. Exp. Med." volume="174" first="561" last="569">
<title>CTLA-4 is a second receptor for the B cell activation antigen B7.</title>
<authorList>
<person name="Linsley P.S."/>
<person name="Brady W."/>
<person name="Urnes M."/>
<person name="Griosmaire L.S."/>
<person name="Damle N.K."/>
<person name="Ledbetter J.A."/>
</authorList>
<dbReference type="PubMed" id="1714933"/>
<dbReference type="DOI" id="10.1084/jem.174.3.561"/>
</citation>
<scope>FUNCTION</scope>
</reference>
<reference key="12">
<citation type="journal article" date="1997" name="Immunity" volume="6" first="583" last="589">
<title>Tyrosine phosphorylation controls internalization of CTLA-4 by regulating its interaction with clathrin-associated adaptor complex AP-2.</title>
<authorList>
<person name="Shiratori T."/>
<person name="Miyatake S."/>
<person name="Ohno H."/>
<person name="Nakaseko C."/>
<person name="Isono K."/>
<person name="Bonifacino J.S."/>
<person name="Saito T."/>
</authorList>
<dbReference type="PubMed" id="9175836"/>
<dbReference type="DOI" id="10.1016/s1074-7613(00)80346-5"/>
</citation>
<scope>PHOSPHORYLATION AT TYR-201</scope>
</reference>
<reference key="13">
<citation type="journal article" date="1998" name="Biochem. Biophys. Res. Commun." volume="252" first="14" last="19">
<title>Resting lymphocyte kinase (Rlk/Txk) phosphorylates the YVKM motif and regulates PI 3-kinase binding to T-cell antigen CTLA-4.</title>
<authorList>
<person name="Schneider H."/>
<person name="Schwartzberg P.L."/>
<person name="Rudd C.E."/>
</authorList>
<dbReference type="PubMed" id="9813138"/>
<dbReference type="DOI" id="10.1006/bbrc.1998.9559"/>
</citation>
<scope>PHOSPHORYLATION AT TYR-201</scope>
</reference>
<reference key="14">
<citation type="journal article" date="2000" name="J. Cell. Biochem." volume="78" first="241" last="250">
<title>Janus kinase 2 is associated with a box 1-like motif and phosphorylates a critical tyrosine residue in the cytoplasmic region of cytotoxic T lymphocyte associated molecule-4.</title>
<authorList>
<person name="Chikuma S."/>
<person name="Murakami M."/>
<person name="Tanaka K."/>
<person name="Uede T."/>
</authorList>
<dbReference type="PubMed" id="10842319"/>
<dbReference type="DOI" id="10.1002/(sici)1097-4644(20000801)78:2&lt;241::aid-jcb7&gt;3.0.co;2-k"/>
</citation>
<scope>PHOSPHORYLATION AT TYR-201 BY JAK2</scope>
</reference>
<reference key="15">
<citation type="journal article" date="2003" name="Nature" volume="423" first="506" last="511">
<title>Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease.</title>
<authorList>
<person name="Ueda H."/>
<person name="Howson J.M."/>
<person name="Esposito L."/>
<person name="Heward J."/>
<person name="Snook H."/>
<person name="Chamberlain G."/>
<person name="Rainbow D.B."/>
<person name="Hunter K.M."/>
<person name="Smith A.N."/>
<person name="Di Genova G."/>
<person name="Herr M.H."/>
<person name="Dahlman I."/>
<person name="Payne F."/>
<person name="Smyth D."/>
<person name="Lowe C."/>
<person name="Twells R.C."/>
<person name="Howlett S."/>
<person name="Healy B."/>
<person name="Nutland S."/>
<person name="Rance H.E."/>
<person name="Everett V."/>
<person name="Smink L.J."/>
<person name="Lam A.C."/>
<person name="Cordell H.J."/>
<person name="Walker N.M."/>
<person name="Bordin C."/>
<person name="Hulme J."/>
<person name="Motzo C."/>
<person name="Cucca F."/>
<person name="Hess J.F."/>
<person name="Metzker M.L."/>
<person name="Rogers J."/>
<person name="Gregory S."/>
<person name="Allahabadia A."/>
<person name="Nithiyananthan R."/>
<person name="Tuomilehto-Wolf E."/>
<person name="Tuomilehto J."/>
<person name="Bingley P."/>
<person name="Gillespie K.M."/>
<person name="Undlien D.E."/>
<person name="Ronningen K.S."/>
<person name="Guja C."/>
<person name="Ionescu-Tirgoviste C."/>
<person name="Savage D.A."/>
<person name="Maxwell A.P."/>
<person name="Carson D.J."/>
<person name="Patterson C.C."/>
<person name="Franklyn J.A."/>
<person name="Clayton D.G."/>
<person name="Peterson L.B."/>
<person name="Wicker L.S."/>
<person name="Todd J.A."/>
<person name="Gough S.C."/>
</authorList>
<dbReference type="PubMed" id="12724780"/>
<dbReference type="DOI" id="10.1038/nature01621"/>
</citation>
<scope>POLYMORPHISM</scope>
</reference>
<reference key="16">
<citation type="journal article" date="2005" name="J. Immunol." volume="175" first="996" last="1004">
<title>Hierarchical regulation of CTLA-4 dimer-based lattice formation and its biological relevance for T cell inactivation.</title>
<authorList>
<person name="Darlington P.J."/>
<person name="Kirchhof M.G."/>
<person name="Criado G."/>
<person name="Sondhi J."/>
<person name="Madrenas J."/>
</authorList>
<dbReference type="PubMed" id="16002699"/>
<dbReference type="DOI" id="10.4049/jimmunol.175.2.996"/>
</citation>
<scope>GLYCOSYLATION AT ASN-113 AND ASN-145</scope>
</reference>
<reference key="17">
<citation type="journal article" date="2006" name="Annu. Rev. Immunol." volume="24" first="65" last="97">
<title>A molecular perspective of CTLA-4 function.</title>
<authorList>
<person name="Teft W.A."/>
<person name="Kirchhof M.G."/>
<person name="Madrenas J."/>
</authorList>
<dbReference type="PubMed" id="16551244"/>
<dbReference type="DOI" id="10.1146/annurev.immunol.24.021605.090535"/>
</citation>
<scope>FUNCTION</scope>
<scope>TISSUE SPECIFICITY</scope>
</reference>
<reference key="18">
<citation type="journal article" date="2008" name="Trends Immunol." volume="29" first="272" last="279">
<title>CTLA-4 trafficking and surface expression.</title>
<authorList>
<person name="Valk E."/>
<person name="Rudd C.E."/>
<person name="Schneider H."/>
</authorList>
<dbReference type="PubMed" id="18468488"/>
<dbReference type="DOI" id="10.1016/j.it.2008.02.011"/>
</citation>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="19">
<citation type="journal article" date="2009" name="Immunol. Rev." volume="229" first="307" last="321">
<title>The clinical utility of inhibiting CD28-mediated costimulation.</title>
<authorList>
<person name="Linsley P.S."/>
<person name="Nadler S.G."/>
</authorList>
<dbReference type="PubMed" id="19426230"/>
<dbReference type="DOI" id="10.1111/j.1600-065x.2009.00780.x"/>
</citation>
<scope>PHARMACEUTICAL</scope>
</reference>
<reference key="20">
<citation type="journal article" date="1997" name="Nat. Struct. Biol." volume="4" first="527" last="531">
<title>Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28.</title>
<authorList>
<person name="Metzler W.J."/>
<person name="Bajorath J."/>
<person name="Fenderson W."/>
<person name="Shaw S.Y."/>
<person name="Constantine K.L."/>
<person name="Naemura J."/>
<person name="Leytze G."/>
<person name="Peach R.J."/>
<person name="Lavoie T.B."/>
<person name="Mueller L."/>
<person name="Linsley P.S."/>
</authorList>
<dbReference type="PubMed" id="9228944"/>
<dbReference type="DOI" id="10.1038/nsb0797-527"/>
</citation>
<scope>STRUCTURE BY NMR OF 37-161</scope>
<scope>DISULFIDE BONDS</scope>
</reference>
<reference key="21">
<citation type="journal article" date="2001" name="Nature" volume="410" first="604" last="608">
<title>Structural basis for co-stimulation by the human CTLA-4/B7-2 complex.</title>
<authorList>
<person name="Schwartz J.C."/>
<person name="Zhang X."/>
<person name="Fedorov A.A."/>
<person name="Nathenson S.G."/>
<person name="Almo S.C."/>
</authorList>
<dbReference type="PubMed" id="11279501"/>
<dbReference type="DOI" id="10.1038/35069112"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 36-161 IN COMPLEX WITH CD86</scope>
<scope>SUBUNIT</scope>
<scope>DISULFIDE BONDS</scope>
</reference>
<reference key="22">
<citation type="journal article" date="2001" name="Nature" volume="410" first="608" last="611">
<title>Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses.</title>
<authorList>
<person name="Stamper C.C."/>
<person name="Zhang Y."/>
<person name="Tobin J.F."/>
<person name="Erbe D.V."/>
<person name="Ikemizu S."/>
<person name="Davis S.J."/>
<person name="Stahl M.L."/>
<person name="Seehra J."/>
<person name="Somers W.S."/>
<person name="Mosyak L."/>
</authorList>
<dbReference type="PubMed" id="11279502"/>
<dbReference type="DOI" id="10.1038/35069118"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 36-161 IN COMPLEX WITH CD80</scope>
<scope>SUBUNIT</scope>
<scope>DISULFIDE BONDS</scope>
<scope>GLYCOSYLATION AT ASN-113 AND ASN-145</scope>
</reference>
<reference key="23">
<citation type="submission" date="2008-01" db="PDB data bank">
<title>High affinity molecular recognition and functional blockade of CTLA-4 by an engineered human lipocalin.</title>
<authorList>
<person name="Schonfeld D.L."/>
<person name="Matschiner G."/>
<person name="Chatwell L."/>
<person name="Trentmann S."/>
<person name="Schlehuber S."/>
<person name="Hohlbaum A."/>
<person name="Skerra A."/>
</authorList>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 38-161</scope>
<scope>DISULFIDE BONDS</scope>
<scope>SUBUNIT</scope>
</reference>
<reference key="24">
<citation type="journal article" date="2011" name="J. Biol. Chem." volume="286" first="6685" last="6696">
<title>Rigid-body ligand recognition drives cytotoxic T-lymphocyte antigen 4 (CTLA-4) receptor triggering.</title>
<authorList>
<person name="Yu C."/>
<person name="Sonnen A.F."/>
<person name="George R."/>
<person name="Dessailly B.H."/>
<person name="Stagg L.J."/>
<person name="Evans E.J."/>
<person name="Orengo C.A."/>
<person name="Stuart D.I."/>
<person name="Ladbury J.E."/>
<person name="Ikemizu S."/>
<person name="Gilbert R.J."/>
<person name="Davis S.J."/>
</authorList>
<dbReference type="PubMed" id="21156796"/>
<dbReference type="DOI" id="10.1074/jbc.m110.182394"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 36-161</scope>
<scope>GLYCOSYLATION AT ASN-113</scope>
<scope>SUBUNIT</scope>
<scope>DISULFIDE BONDS</scope>
</reference>
<reference key="25" evidence="7">
<citation type="journal article" date="2017" name="Proc. Natl. Acad. Sci. U.S.A." volume="114" first="E4223" last="E4232">
<title>Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab.</title>
<authorList>
<person name="Ramagopal U.A."/>
<person name="Liu W."/>
<person name="Garrett-Thomson S.C."/>
<person name="Bonanno J.B."/>
<person name="Yan Q."/>
<person name="Srinivasan M."/>
<person name="Wong S.C."/>
<person name="Bell A."/>
<person name="Mankikar S."/>
<person name="Rangan V.S."/>
<person name="Deshpande S."/>
<person name="Korman A.J."/>
<person name="Almo S.C."/>
</authorList>
<dbReference type="PubMed" id="28484017"/>
<dbReference type="DOI" id="10.1073/pnas.1617941114"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 37-154 IN COMPLEX WITH THERAPEUTIC ANTIBODY IPILIMUMAB</scope>
<scope>SUBUNIT</scope>
<scope>INTERACTION WITH CD80; CD86 AND ICOSLG</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>TOPOLOGY</scope>
<scope>DISULFIDE BONDS</scope>
<scope>MUTAGENESIS OF VAL-45; LEU-47; SER-49; ARG-70; LYS-130; GLU-132; TYR-139 AND ILE-143</scope>
</reference>
<reference key="26">
<citation type="journal article" date="1997" name="Hum. Mol. Genet." volume="6" first="1275" last="1282">
<title>Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA4 polymorphisms in multiple ethnic groups.</title>
<authorList>
<person name="Marron M.P."/>
<person name="Raffel L.J."/>
<person name="Garchon H.-J."/>
<person name="Jacob C.O."/>
<person name="Serrano-Rios M."/>
<person name="Martinez Larrad M.T."/>
<person name="Teng W.-P."/>
<person name="Park Y."/>
<person name="Zhang Z.-X."/>
<person name="Goldstein D.R."/>
<person name="Tao Y.-W."/>
<person name="Beaurain G."/>
<person name="Bach J.-F."/>
<person name="Huang H.-S."/>
<person name="Luo D.-F."/>
<person name="Zeidler A."/>
<person name="Rotter J.I."/>
<person name="Yang M.C.K."/>
<person name="Modilevsky T."/>
<person name="Maclaren N.K."/>
<person name="She J.-X."/>
</authorList>
<dbReference type="PubMed" id="9259273"/>
<dbReference type="DOI" id="10.1093/hmg/6.8.1275"/>
</citation>
<scope>VARIANT ALA-17</scope>
<scope>INVOLVEMENT IN IDDM12</scope>
</reference>
<reference key="27">
<citation type="journal article" date="1998" name="Gut" volume="43" first="187" last="189">
<title>CTLA-4 gene polymorphism is associated with predisposition to coeliac disease.</title>
<authorList>
<person name="Djilali-Saiah I."/>
<person name="Schmitz J."/>
<person name="Harfouch-Hammoud E."/>
<person name="Mougenot J.-F."/>
<person name="Bach J.-F."/>
<person name="Caillat-Zucman S."/>
</authorList>
<dbReference type="PubMed" id="10189842"/>
<dbReference type="DOI" id="10.1136/gut.43.2.187"/>
</citation>
<scope>POLYMORPHISM</scope>
<scope>INVOLVEMENT IN CELIAC3</scope>
</reference>
<reference key="28">
<citation type="journal article" date="1999" name="Lancet" volume="354" first="743" last="744">
<title>Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism confers susceptibility to thyroid associated orbitopathy.</title>
<authorList>
<person name="Vaidya B."/>
<person name="Imrie H."/>
<person name="Perros P."/>
<person name="Dickinson J."/>
<person name="McCarthy M.I."/>
<person name="Kendall-Taylor P."/>
<person name="Pearce S.H.S."/>
</authorList>
<dbReference type="PubMed" id="10475192"/>
<dbReference type="DOI" id="10.1016/s0140-6736(99)01465-8"/>
</citation>
<scope>VARIANT ALA-17</scope>
<scope>INVOLVEMENT IN THYROID ASSOCIATED ORBITOPATHY</scope>
</reference>
<reference key="29">
<citation type="journal article" date="2000" name="Mol. Genet. Metab." volume="70" first="214" last="218">
<title>Complex association analysis of Graves disease using a set of polymorphic markers.</title>
<authorList>
<person name="Chistyakov D.A."/>
<person name="Savost'anov K.V."/>
<person name="Turakulov R.I."/>
<person name="Petunina N.A."/>
<person name="Trukhina L.V."/>
<person name="Kudinova A.V."/>
<person name="Balabolkin M.I."/>
<person name="Nosikov V.V."/>
</authorList>
<dbReference type="PubMed" id="10924276"/>
<dbReference type="DOI" id="10.1006/mgme.2000.3007"/>
</citation>
<scope>POLYMORPHISM</scope>
<scope>VARIANT ALA-17</scope>
<scope>INVOLVEMENT IN GRAVES DISEASE</scope>
</reference>
<reference key="30">
<citation type="journal article" date="2000" name="Am. J. Hum. Genet." volume="67" first="737" last="744">
<title>Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene.</title>
<authorList>
<person name="Deng Z."/>
<person name="Morse J.H."/>
<person name="Slager S.L."/>
<person name="Cuervo N."/>
<person name="Moore K.J."/>
<person name="Venetos G."/>
<person name="Kalachikov S."/>
<person name="Cayanis E."/>
<person name="Fischer S.G."/>
<person name="Barst R.J."/>
<person name="Hodge S.E."/>
<person name="Knowles J.A."/>
</authorList>
<dbReference type="PubMed" id="10903931"/>
<dbReference type="DOI" id="10.1086/303059"/>
</citation>
<scope>VARIANT ALA-17</scope>
</reference>
<reference key="31">
<citation type="journal article" date="2004" name="Eur. J. Hum. Genet." volume="12" first="620" last="626">
<title>Evidence for CTLA4 as a susceptibility gene for systemic lupus erythematosus.</title>
<authorList>
<person name="Barreto M."/>
<person name="Santos E."/>
<person name="Ferreira R."/>
<person name="Fesel C."/>
<person name="Fontes M.F."/>
<person name="Pereira C."/>
<person name="Martins B."/>
<person name="Andreia R."/>
<person name="Viana J.F."/>
<person name="Crespo F."/>
<person name="Vasconcelos C."/>
<person name="Ferreira C."/>
<person name="Vicente A.M."/>
</authorList>
<dbReference type="PubMed" id="15138458"/>
<dbReference type="DOI" id="10.1038/sj.ejhg.5201214"/>
</citation>
<scope>POLYMORPHISM</scope>
<scope>INVOLVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS</scope>
</reference>
<reference key="32">
<citation type="journal article" date="2004" name="J. Virol." volume="78" first="11258" last="11262">
<title>Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B virus infection.</title>
<authorList>
<person name="Thio C.L."/>
<person name="Mosbruger T.L."/>
<person name="Kaslow R.A."/>
<person name="Karp C.L."/>
<person name="Strathdee S.A."/>
<person name="Vlahov D."/>
<person name="O'Brien S.J."/>
<person name="Astemborski J."/>
<person name="Thomas D.L."/>
</authorList>
<dbReference type="PubMed" id="15452244"/>
<dbReference type="DOI" id="10.1128/jvi.78.20.11258-11262.2004"/>
</citation>
<scope>POLYMORPHISM</scope>
<scope>INVOLVEMENT IN SUSCEPTIBILITY TO HBV INFECTION</scope>
<scope>VARIANT ALA-17</scope>
</reference>
<reference key="33">
<citation type="journal article" date="2005" name="Eur. J. Hum. Genet." volume="13" first="440" last="444">
<title>A common CTLA4 haplotype associated with coeliac disease.</title>
<authorList>
<person name="Hunt K.A."/>
<person name="McGovern D.P.B."/>
<person name="Kumar P.J."/>
<person name="Ghosh S."/>
<person name="Travis S.P.L."/>
<person name="Walters J.R.F."/>
<person name="Jewell D.P."/>
<person name="Playford R.J."/>
<person name="van Heel D.A."/>
</authorList>
<dbReference type="PubMed" id="15657618"/>
<dbReference type="DOI" id="10.1038/sj.ejhg.5201357"/>
</citation>
<scope>POLYMORPHISM</scope>
<scope>INVOLVEMENT IN CELIAC3</scope>
</reference>
<reference key="34">
<citation type="journal article" date="2005" name="Hum. Genet." volume="116" first="361" last="367">
<title>CTLA-4 polymorphisms and systemic lupus erythematosus (SLE): a meta-analysis.</title>
<authorList>
<person name="Lee Y.H."/>
<person name="Harley J.B."/>
<person name="Nath S.K."/>
</authorList>
<dbReference type="PubMed" id="15688186"/>
<dbReference type="DOI" id="10.1007/s00439-004-1244-1"/>
</citation>
<scope>POLYMORPHISM</scope>
<scope>INVOLVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS</scope>
</reference>
<reference key="35">
<citation type="journal article" date="2014" name="Nat. Med." volume="20" first="1410" last="1416">
<title>Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations.</title>
<authorList>
<person name="Schubert D."/>
<person name="Bode C."/>
<person name="Kenefeck R."/>
<person name="Hou T.Z."/>
<person name="Wing J.B."/>
<person name="Kennedy A."/>
<person name="Bulashevska A."/>
<person name="Petersen B.S."/>
<person name="Schaeffer A.A."/>
<person name="Gruening B.A."/>
<person name="Unger S."/>
<person name="Frede N."/>
<person name="Baumann U."/>
<person name="Witte T."/>
<person name="Schmidt R.E."/>
<person name="Dueckers G."/>
<person name="Niehues T."/>
<person name="Seneviratne S."/>
<person name="Kanariou M."/>
<person name="Speckmann C."/>
<person name="Ehl S."/>
<person name="Rensing-Ehl A."/>
<person name="Warnatz K."/>
<person name="Rakhmanov M."/>
<person name="Thimme R."/>
<person name="Hasselblatt P."/>
<person name="Emmerich F."/>
<person name="Cathomen T."/>
<person name="Backofen R."/>
<person name="Fisch P."/>
<person name="Seidl M."/>
<person name="May A."/>
<person name="Schmitt-Graeff A."/>
<person name="Ikemizu S."/>
<person name="Salzer U."/>
<person name="Franke A."/>
<person name="Sakaguchi S."/>
<person name="Walker L.S."/>
<person name="Sansom D.M."/>
<person name="Grimbacher B."/>
</authorList>
<dbReference type="PubMed" id="25329329"/>
<dbReference type="DOI" id="10.1038/nm.3746"/>
</citation>
<scope>POLYMORPHISM</scope>
<scope>INVOLVEMENT IN ALPS5</scope>
<scope>VARIANT ALPS5 TRP-70</scope>
</reference>
<reference key="36">
<citation type="journal article" date="2014" name="Science" volume="345" first="1623" last="1627">
<title>Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4.</title>
<authorList>
<person name="Kuehn H.S."/>
<person name="Ouyang W."/>
<person name="Lo B."/>
<person name="Deenick E.K."/>
<person name="Niemela J.E."/>
<person name="Avery D.T."/>
<person name="Schickel J.N."/>
<person name="Tran D.Q."/>
<person name="Stoddard J."/>
<person name="Zhang Y."/>
<person name="Frucht D.M."/>
<person name="Dumitriu B."/>
<person name="Scheinberg P."/>
<person name="Folio L.R."/>
<person name="Frein C.A."/>
<person name="Price S."/>
<person name="Koh C."/>
<person name="Heller T."/>
<person name="Seroogy C.M."/>
<person name="Huttenlocher A."/>
<person name="Rao V.K."/>
<person name="Su H.C."/>
<person name="Kleiner D."/>
<person name="Notarangelo L.D."/>
<person name="Rampertaap Y."/>
<person name="Olivier K.N."/>
<person name="McElwee J."/>
<person name="Hughes J."/>
<person name="Pittaluga S."/>
<person name="Oliveira J.B."/>
<person name="Meffre E."/>
<person name="Fleisher T.A."/>
<person name="Holland S.M."/>
<person name="Lenardo M.J."/>
<person name="Tangye S.G."/>
<person name="Uzel G."/>
</authorList>
<dbReference type="PubMed" id="25213377"/>
<dbReference type="DOI" id="10.1126/science.1255904"/>
</citation>
<scope>POLYMORPHISM</scope>
<scope>INVOLVEMENT IN ALPS5</scope>
</reference>
<comment type="function">
<text evidence="23 25">Inhibitory receptor acting as a major negative regulator of T-cell responses. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28.</text>
</comment>
<comment type="subunit">
<text evidence="15 16 28 31 36">Homodimer; disulfide-linked (PubMed:11279501, PubMed:11279502, Ref.23, PubMed:21156796, PubMed:28484017). Binds to CD80/B7-1 and CD86/B7.2 (PubMed:11279501, PubMed:11279502, PubMed:28484017). Interacts with ICOSLG (PubMed:28484017).</text>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1030991">
<id>P16410</id>
</interactant>
<interactant intactId="EBI-1031024">
<id>P33681</id>
<label>CD80</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>7</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1030991">
<id>P16410</id>
</interactant>
<interactant intactId="EBI-1030956">
<id>P42081</id>
<label>CD86</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1030991">
<id>P16410</id>
</interactant>
<interactant intactId="EBI-12019274">
<id>Q4LDR2</id>
<label>CTXN3</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1030991">
<id>P16410</id>
</interactant>
<interactant intactId="EBI-750078">
<id>Q13021</id>
<label>MALL</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1030991">
<id>P16410</id>
</interactant>
<interactant intactId="EBI-79464">
<id>P27986</id>
<label>PIK3R1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1030991">
<id>P16410</id>
</interactant>
<interactant intactId="EBI-10173151">
<id>A2RU14</id>
<label>TMEM218</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="subcellular location">
<subcellularLocation>
<location evidence="26 31">Cell membrane</location>
<topology evidence="26 31">Single-pass type I membrane protein</topology>
</subcellularLocation>
<text>Exists primarily an intracellular antigen whose surface expression is tightly regulated by restricted trafficking to the cell surface and rapid internalisation;.</text>
</comment>
<comment type="alternative products">
<event type="alternative splicing"/>
<isoform>
<id>P16410-1</id>
<name>1</name>
<sequence type="displayed"/>
</isoform>
<isoform>
<id>P16410-2</id>
<name>2</name>
<name>ss-CTLA-4</name>
<sequence type="described" ref="VSP_041284"/>
</isoform>
<isoform>
<id>P16410-3</id>
<name>3</name>
<sequence type="described" ref="VSP_041284 VSP_041287"/>
</isoform>
<isoform>
<id>P16410-4</id>
<name>4</name>
<sequence type="described" ref="VSP_041285 VSP_041286 VSP_041287"/>
</isoform>
<isoform>
<id>P16410-5</id>
<name>5</name>
<sequence type="described" ref="VSP_047238 VSP_047239"/>
</isoform>
</comment>
<comment type="tissue specificity">
<text evidence="11 23 24">Widely expressed with highest levels in lymphoid tissues. Detected in activated T-cells where expression levels are 30- to 50-fold less than CD28, the stimulatory coreceptor, on the cell surface following activation.</text>
</comment>
<comment type="PTM">
<text evidence="16 22 28">N-glycosylation is important for dimerization.</text>
</comment>
<comment type="PTM">
<text evidence="12 32 35">Phosphorylation at Tyr-201 prevents binding to the AP-2 adapter complex, blocks endocytosis, and leads to retention of CTLA4 on the cell surface.</text>
</comment>
<comment type="polymorphism">
<text evidence="9 14 17 18 19 20 21 27 29 30">Genetic variations in CTLA4 are associated with susceptibility to several autoimmune disorders (PubMed:18595775, PubMed:12724780, PubMed:10189842, PubMed:10924276, PubMed:15138458, PubMed:15657618, PubMed:15688186, PubMed:25329329, PubMed:25213377). They influence responsiveness to hepatitis B virus (HBV) infection [MIM:610424] (PubMed:15452244).</text>
</comment>
<comment type="disease" evidence="18 21">
<disease id="DI-02648">
<name>Systemic lupus erythematosus</name>
<acronym>SLE</acronym>
<description>A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.</description>
<dbReference type="MIM" id="152700"/>
</disease>
<text>Disease susceptibility is associated with variations affecting the gene represented in this entry.</text>
</comment>
<comment type="disease">
<text evidence="14">Genetic variations in CTLA4 may influence susceptibility to Graves disease, an autoimmune disorder associated with overactivity of the thyroid gland and hyperthyroidism.</text>
</comment>
<comment type="disease" evidence="34">
<disease id="DI-02777">
<name>Diabetes mellitus, insulin-dependent, 12</name>
<acronym>IDDM12</acronym>
<description>A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical features are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.</description>
<dbReference type="MIM" id="601388"/>
</disease>
<text>Disease susceptibility is associated with variations affecting the gene represented in this entry.</text>
</comment>
<comment type="disease" evidence="9 20">
<disease id="DI-02883">
<name>Celiac disease 3</name>
<acronym>CELIAC3</acronym>
<description>A multifactorial, chronic disorder of the small intestine caused by intolerance to gluten. It is characterized by immune-mediated enteropathy associated with failed intestinal absorption, and malnutrition. In predisposed individuals, the ingestion of gluten-containing food such as wheat and rye induces a flat jejunal mucosa with infiltration of lymphocytes.</description>
<dbReference type="MIM" id="609755"/>
</disease>
<text>Disease susceptibility is associated with variations affecting the gene represented in this entry.</text>
</comment>
<comment type="disease" evidence="29 30">
<disease id="DI-04302">
<name>Autoimmune lymphoproliferative syndrome 5</name>
<acronym>ALPS5</acronym>
<description>An autosomal dominant primary immunodeficiency characterized by severe autoimmunity, infiltration of non-lymphoid organs, such as the intestine, lungs and brain, by hyperactive T cells and B cells, autoimmune cytopenias, and hypogammaglobulinemia in early childhood.</description>
<dbReference type="MIM" id="616100"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="pharmaceutical">
<text>Engineered fusion proteins consisting of the extracellular domain of CTLA4 and the IgG Fc region (Ctla4-Ig), inhibit T-cell-dependent antibody responses, and are used as immunosuppressive agents. They are soluble, have an enhanced affinity for B7 ligands and act as a competitive inhibitor of CD28.</text>
</comment>
<comment type="miscellaneous">
<text>The therapeutic antibody Ipilimumab competes for the binding site of the endogenous ligands CD80/B7-1, CD86/B7-2 and ICOSLG.</text>
</comment>
<comment type="online information" name="Wikipedia">
<link uri="https://en.wikipedia.org/wiki/CTLA-4"/>
<text>CLTA-4 entry</text>
</comment>
<dbReference type="EMBL" id="L15006">
<property type="protein sequence ID" value="AAB59385.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="M74363">
<property type="protein sequence ID" value="AAA52127.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AF411058">
<property type="protein sequence ID" value="AAL40932.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AY792514">
<property type="protein sequence ID" value="AAV66331.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AY999702">
<property type="protein sequence ID" value="AAY00166.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="DQ785106">
<property type="protein sequence ID" value="ABG85285.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AF414120">
<property type="protein sequence ID" value="AAL07473.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="DQ357942">
<property type="protein sequence ID" value="ABC67470.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AC010138">
<property type="protein sequence ID" value="AAX93176.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="BC074842">
<property type="protein sequence ID" value="AAH74842.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="BC074893">
<property type="protein sequence ID" value="AAH74893.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AH002733">
<property type="protein sequence ID" value="AAA52773.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="U90273">
<property type="protein sequence ID" value="AAD00698.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AF142144">
<property type="protein sequence ID" value="AAF02499.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="CCDS" id="CCDS2362.1">
<molecule id="P16410-1"/>
</dbReference>
<dbReference type="CCDS" id="CCDS42803.1">
<molecule id="P16410-5"/>
</dbReference>
<dbReference type="PIR" id="S08614">
<property type="entry name" value="S08614"/>
</dbReference>
<dbReference type="RefSeq" id="NP_001032720.1">
<molecule id="P16410-5"/>
<property type="nucleotide sequence ID" value="NM_001037631.2"/>
</dbReference>
<dbReference type="RefSeq" id="NP_005205.2">
<molecule id="P16410-1"/>
<property type="nucleotide sequence ID" value="NM_005214.4"/>
</dbReference>
<dbReference type="PDB" id="1AH1">
<property type="method" value="NMR"/>
<property type="chains" value="A=37-161"/>
</dbReference>
<dbReference type="PDB" id="1H6E">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.60"/>
<property type="chains" value="P=197-207"/>
</dbReference>
<dbReference type="PDB" id="1I85">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.20"/>
<property type="chains" value="C/D=36-161"/>
</dbReference>
<dbReference type="PDB" id="1I8L">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.00"/>
<property type="chains" value="C/D=36-161"/>
</dbReference>
<dbReference type="PDB" id="2X44">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.60"/>
<property type="chains" value="D=36-161"/>
</dbReference>
<dbReference type="PDB" id="3BX7">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.10"/>
<property type="chains" value="C=38-161"/>
</dbReference>
<dbReference type="PDB" id="3OSK">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.80"/>
<property type="chains" value="A/B=36-161"/>
</dbReference>
<dbReference type="PDB" id="5GGV">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.00"/>
<property type="chains" value="Y=36-161"/>
</dbReference>
<dbReference type="PDB" id="5TRU">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.00"/>
<property type="chains" value="C/c=37-154"/>
</dbReference>
<dbReference type="PDB" id="5XJ3">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.20"/>
<property type="chains" value="C/F/I/L=36-161"/>
</dbReference>
<dbReference type="PDB" id="6RP8">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.60"/>
<property type="chains" value="C/c=37-154"/>
</dbReference>
<dbReference type="PDB" id="6RPJ">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.25"/>
<property type="chains" value="A/C/E/G=37-156"/>
</dbReference>
<dbReference type="PDB" id="6RQM">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.00"/>
<property type="chains" value="A=37-161"/>
</dbReference>
<dbReference type="PDBsum" id="1AH1"/>
<dbReference type="PDBsum" id="1H6E"/>
<dbReference type="PDBsum" id="1I85"/>
<dbReference type="PDBsum" id="1I8L"/>
<dbReference type="PDBsum" id="2X44"/>
<dbReference type="PDBsum" id="3BX7"/>
<dbReference type="PDBsum" id="3OSK"/>
<dbReference type="PDBsum" id="5GGV"/>
<dbReference type="PDBsum" id="5TRU"/>
<dbReference type="PDBsum" id="5XJ3"/>
<dbReference type="PDBsum" id="6RP8"/>
<dbReference type="PDBsum" id="6RPJ"/>
<dbReference type="PDBsum" id="6RQM"/>
<dbReference type="SMR" id="P16410"/>
<dbReference type="BioGRID" id="107875">
<property type="interactions" value="112"/>
</dbReference>
<dbReference type="DIP" id="DIP-35607N"/>
<dbReference type="ELM" id="P16410"/>
<dbReference type="IntAct" id="P16410">
<property type="interactions" value="15"/>
</dbReference>
<dbReference type="MINT" id="P16410"/>
<dbReference type="STRING" id="9606.ENSP00000303939"/>
<dbReference type="ChEMBL" id="CHEMBL2364164"/>
<dbReference type="DrugBank" id="DB06186">
<property type="generic name" value="Ipilimumab"/>
</dbReference>
<dbReference type="DrugCentral" id="P16410"/>
<dbReference type="GuidetoPHARMACOLOGY" id="2743"/>
<dbReference type="GlyGen" id="P16410">
<property type="glycosylation" value="2 sites"/>
</dbReference>
<dbReference type="iPTMnet" id="P16410"/>
<dbReference type="PhosphoSitePlus" id="P16410"/>
<dbReference type="BioMuta" id="CTLA4"/>
<dbReference type="DMDM" id="27735177"/>
<dbReference type="PaxDb" id="P16410"/>
<dbReference type="PeptideAtlas" id="P16410"/>
<dbReference type="PRIDE" id="P16410"/>
<dbReference type="ProteomicsDB" id="50980"/>
<dbReference type="ProteomicsDB" id="53354">
<molecule id="P16410-1"/>
</dbReference>
<dbReference type="ProteomicsDB" id="53355">
<molecule id="P16410-2"/>
</dbReference>
<dbReference type="ProteomicsDB" id="53356">
<molecule id="P16410-3"/>
</dbReference>
<dbReference type="ProteomicsDB" id="53357">
<molecule id="P16410-4"/>
</dbReference>
<dbReference type="ABCD" id="P16410">
<property type="antibodies" value="160 sequenced antibodies"/>
</dbReference>
<dbReference type="Antibodypedia" id="19961">
<property type="antibodies" value="1565 antibodies"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000295854">
<molecule id="P16410-5"/>
<property type="protein sequence ID" value="ENSP00000295854"/>
<property type="gene ID" value="ENSG00000163599"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000472206">
<molecule id="P16410-4"/>
<property type="protein sequence ID" value="ENSP00000417779"/>
<property type="gene ID" value="ENSG00000163599"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000487393">
<molecule id="P16410-3"/>
<property type="protein sequence ID" value="ENSP00000497319"/>
<property type="gene ID" value="ENSG00000163599"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000648405">
<molecule id="P16410-1"/>
<property type="protein sequence ID" value="ENSP00000497102"/>
<property type="gene ID" value="ENSG00000163599"/>
</dbReference>
<dbReference type="GeneID" id="1493"/>
<dbReference type="KEGG" id="hsa:1493"/>
<dbReference type="UCSC" id="uc002vak.3">
<molecule id="P16410-1"/>
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="CTD" id="1493"/>
<dbReference type="DisGeNET" id="1493"/>
<dbReference type="EuPathDB" id="HostDB:ENSG00000163599.14"/>
<dbReference type="GeneCards" id="CTLA4"/>
<dbReference type="HGNC" id="HGNC:2505">
<property type="gene designation" value="CTLA4"/>
</dbReference>
<dbReference type="HPA" id="ENSG00000163599">
<property type="expression patterns" value="Tissue enhanced (blood, lymphoid tissue)"/>
</dbReference>
<dbReference type="MalaCards" id="CTLA4"/>
<dbReference type="MIM" id="109100">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="123890">
<property type="type" value="gene"/>
</dbReference>
<dbReference type="MIM" id="152700">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="601388">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="609755">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="610424">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="616100">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="neXtProt" id="NX_P16410"/>
<dbReference type="OpenTargets" id="ENSG00000163599"/>
<dbReference type="Orphanet" id="391490">
<property type="disease" value="Adult-onset myasthenia gravis"/>
</dbReference>
<dbReference type="Orphanet" id="436159">
<property type="disease" value="Autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency"/>
</dbReference>
<dbReference type="Orphanet" id="2584">
<property type="disease" value="Classic mycosis fungoides"/>
</dbReference>
<dbReference type="Orphanet" id="900">
<property type="disease" value="Granulomatosis with polyangiitis"/>
</dbReference>
<dbReference type="Orphanet" id="3162">
<property type="disease" value="Sezary syndrome"/>
</dbReference>
<dbReference type="Orphanet" id="536">
<property type="disease" value="Systemic lupus erythematosus"/>
</dbReference>
<dbReference type="PharmGKB" id="PA27006"/>
<dbReference type="eggNOG" id="ENOG502RZVK">
<property type="taxonomic scope" value="Eukaryota"/>
</dbReference>
<dbReference type="GeneTree" id="ENSGT00530000063873"/>
<dbReference type="HOGENOM" id="CLU_085095_0_0_1"/>
<dbReference type="InParanoid" id="P16410"/>
<dbReference type="KO" id="K06538"/>
<dbReference type="OMA" id="YVKMPSE"/>
<dbReference type="OrthoDB" id="1222373at2759"/>
<dbReference type="PhylomeDB" id="P16410"/>
<dbReference type="TreeFam" id="TF335679"/>
<dbReference type="PathwayCommons" id="P16410"/>
<dbReference type="Reactome" id="R-HSA-389513">
<property type="pathway name" value="CTLA4 inhibitory signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-8877330">
<property type="pathway name" value="RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs)"/>
</dbReference>
<dbReference type="SIGNOR" id="P16410"/>
<dbReference type="BioGRID-ORCS" id="1493">
<property type="hits" value="2 hits in 873 CRISPR screens"/>
</dbReference>
<dbReference type="EvolutionaryTrace" id="P16410"/>
<dbReference type="GeneWiki" id="CTLA-4"/>
<dbReference type="GenomeRNAi" id="1493"/>
<dbReference type="Pharos" id="P16410">
<property type="development level" value="Tclin"/>
</dbReference>
<dbReference type="PRO" id="PR:P16410"/>
<dbReference type="Proteomes" id="UP000005640">
<property type="component" value="Chromosome 2"/>
</dbReference>
<dbReference type="RNAct" id="P16410">
<property type="molecule type" value="protein"/>
</dbReference>
<dbReference type="Bgee" id="ENSG00000163599">
<property type="expression patterns" value="Expressed in lymph node and 129 other tissues"/>
</dbReference>
<dbReference type="Genevisible" id="P16410">
<property type="organism ID" value="HS"/>
</dbReference>
<dbReference type="GO" id="GO:0045334">
<property type="term" value="C:clathrin-coated endocytic vesicle"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0009897">
<property type="term" value="C:external side of plasma membrane"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0005794">
<property type="term" value="C:Golgi apparatus"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0005887">
<property type="term" value="C:integral component of plasma membrane"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0048471">
<property type="term" value="C:perinuclear region of cytoplasm"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0005886">
<property type="term" value="C:plasma membrane"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0098636">
<property type="term" value="C:protein complex involved in cell adhesion"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="MGI"/>
</dbReference>
<dbReference type="GO" id="GO:0002250">
<property type="term" value="P:adaptive immune response"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="GO" id="GO:0050853">
<property type="term" value="P:B cell receptor signaling pathway"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0006974">
<property type="term" value="P:cellular response to DNA damage stimulus"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0006955">
<property type="term" value="P:immune response"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="ProtInc"/>
</dbReference>
<dbReference type="GO" id="GO:0002376">
<property type="term" value="P:immune system process"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0030889">
<property type="term" value="P:negative regulation of B cell proliferation"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0050777">
<property type="term" value="P:negative regulation of immune response"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0045590">
<property type="term" value="P:negative regulation of regulatory T cell differentiation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0042130">
<property type="term" value="P:negative regulation of T cell proliferation"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0043065">
<property type="term" value="P:positive regulation of apoptotic process"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0045589">
<property type="term" value="P:regulation of regulatory T cell differentiation"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0031295">
<property type="term" value="P:T cell costimulation"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0050852">
<property type="term" value="P:T cell receptor signaling pathway"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="Gene3D" id="2.60.40.10">
<property type="match status" value="1"/>
</dbReference>
<dbReference type="InterPro" id="IPR008096">
<property type="entry name" value="CTLA4"/>
</dbReference>
<dbReference type="InterPro" id="IPR040216">
<property type="entry name" value="CTLA4/CD28"/>
</dbReference>
<dbReference type="InterPro" id="IPR036179">
<property type="entry name" value="Ig-like_dom_sf"/>
</dbReference>
<dbReference type="InterPro" id="IPR013783">
<property type="entry name" value="Ig-like_fold"/>
</dbReference>
<dbReference type="InterPro" id="IPR003599">
<property type="entry name" value="Ig_sub"/>
</dbReference>
<dbReference type="InterPro" id="IPR013106">
<property type="entry name" value="Ig_V-set"/>
</dbReference>
<dbReference type="PANTHER" id="PTHR11494">
<property type="entry name" value="PTHR11494"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PANTHER" id="PTHR11494:SF8">
<property type="entry name" value="PTHR11494:SF8"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF07686">
<property type="entry name" value="V-set"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PRINTS" id="PR01720">
<property type="entry name" value="CTLANTIGEN4"/>
</dbReference>
<dbReference type="SMART" id="SM00409">
<property type="entry name" value="IG"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SMART" id="SM00406">
<property type="entry name" value="IGv"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF48726">
<property type="entry name" value="SSF48726"/>
<property type="match status" value="1"/>
</dbReference>
<proteinExistence type="evidence at protein level"/>
<keyword id="KW-0002">3D-structure</keyword>
<keyword id="KW-1064">Adaptive immunity</keyword>
<keyword id="KW-0025">Alternative splicing</keyword>
<keyword id="KW-1003">Cell membrane</keyword>
<keyword id="KW-0219">Diabetes mellitus</keyword>
<keyword id="KW-0225">Disease mutation</keyword>
<keyword id="KW-1015">Disulfide bond</keyword>
<keyword id="KW-0325">Glycoprotein</keyword>
<keyword id="KW-0391">Immunity</keyword>
<keyword id="KW-0393">Immunoglobulin domain</keyword>
<keyword id="KW-0472">Membrane</keyword>
<keyword id="KW-0582">Pharmaceutical</keyword>
<keyword id="KW-0597">Phosphoprotein</keyword>
<keyword id="KW-0621">Polymorphism</keyword>
<keyword id="KW-1185">Reference proteome</keyword>
<keyword id="KW-0732">Signal</keyword>
<keyword id="KW-0772">Systemic lupus erythematosus</keyword>
<keyword id="KW-0812">Transmembrane</keyword>
<keyword id="KW-1133">Transmembrane helix</keyword>
<feature type="signal peptide" evidence="8">
<location>
<begin position="1"/>
<end position="35"/>
</location>
</feature>
<feature type="chain" description="Cytotoxic T-lymphocyte protein 4" id="PRO_0000014734">
<location>
<begin position="36"/>
<end position="223"/>
</location>
</feature>
<feature type="topological domain" description="Extracellular" evidence="40">
<location>
<begin position="36"/>
<end position="161"/>
</location>
</feature>
<feature type="transmembrane region" description="Helical" evidence="8">
<location>
<begin position="162"/>
<end position="182"/>
</location>
</feature>
<feature type="topological domain" description="Cytoplasmic" evidence="8">
<location>
<begin position="183"/>
<end position="223"/>
</location>
</feature>
<feature type="domain" description="Ig-like V-type">
<location>
<begin position="39"/>
<end position="140"/>
</location>
</feature>
<feature type="region of interest" description="Homodimerization" evidence="28">
<location>
<begin position="46"/>
<end position="50"/>
</location>
</feature>
<feature type="region of interest" description="Important for interaction with CD80 and CD86" evidence="31">
<location>
<begin position="134"/>
<end position="139"/>
</location>
</feature>
<feature type="region of interest" description="Homodimerization" evidence="28 31">
<location>
<begin position="150"/>
<end position="155"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by TXK and JAK2" evidence="12 32 35">
<location>
<position position="201"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="16 22 28">
<location>
<position position="113"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="16 22">
<location>
<position position="145"/>
</location>
</feature>
<feature type="disulfide bond" evidence="4 7 15 16 28 31 33 36">
<location>
<begin position="58"/>
<end position="129"/>
</location>
</feature>
<feature type="disulfide bond" evidence="4 7 15 16 28 31 33 36">
<location>
<begin position="85"/>
<end position="103"/>
</location>
</feature>
<feature type="disulfide bond" description="Interchain" evidence="4 31 36">
<location>
<position position="157"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 2 and isoform 3." id="VSP_041284" evidence="37">
<location>
<begin position="38"/>
<end position="204"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 4." id="VSP_041285" evidence="37">
<original>C</original>
<variation>S</variation>
<location>
<position position="58"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 4." id="VSP_041286" evidence="37">
<location>
<begin position="59"/>
<end position="204"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 5." id="VSP_047238" evidence="38">
<original>DPEPCPDSDFLLWILAAVSSGL</original>
<variation>AKEKKPSYNRGLCENAPNRARM</variation>
<location>
<begin position="153"/>
<end position="174"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 5." id="VSP_047239" evidence="38">
<location>
<begin position="175"/>
<end position="223"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 3 and isoform 4." id="VSP_041287" evidence="37">
<original>PPTEPECEKQFQPYFIPIN</original>
<variation>KEKKPSYNRGLCENAPNRARM</variation>
<location>
<begin position="205"/>
<end position="223"/>
</location>
</feature>
<feature type="sequence variant" description="Increased risk for Graves disease, insulin-dependent diabetes mellitus, thyroid-associated orbitopathy, systemic lupus erythematosus and susceptibility to HBV infection; dbSNP:rs231775." id="VAR_013577" evidence="10 13 14 19 24 27 34">
<original>T</original>
<variation>A</variation>
<location>
<position position="17"/>
</location>
</feature>
<feature type="sequence variant" description="In ALPS5; dbSNP:rs606231422." id="VAR_072681" evidence="30">
<original>R</original>
<variation>W</variation>
<location>
<position position="70"/>
</location>
</feature>
<feature type="mutagenesis site" description="Strongly reduced interaction with CD80, CD86 and ICOSLG." evidence="31">
<original>V</original>
<variation>D</variation>
<location>
<position position="45"/>
</location>
</feature>
<feature type="mutagenesis site" description="Strongly reduced interaction with CD80, CD86 and ICOSLG." evidence="31">
<original>L</original>
<variation>D</variation>
<location>
<position position="47"/>
</location>
</feature>
<feature type="mutagenesis site" description="Strongly reduced interaction with CD80, CD86 and ICOSLG." evidence="31">
<original>S</original>
<variation>A</variation>
<location>
<position position="49"/>
</location>
</feature>
<feature type="mutagenesis site" description="Strongly reduced interaction with CD80, CD86 and ICOSLG." evidence="31">
<original>R</original>
<variation>A</variation>
<variation>D</variation>
<location>
<position position="70"/>
</location>
</feature>
<feature type="mutagenesis site" description="Strongly reduced interaction with CD80, CD86 and ICOSLG." evidence="31">
<original>K</original>
<variation>A</variation>
<variation>D</variation>
<location>
<position position="130"/>
</location>
</feature>
<feature type="mutagenesis site" description="Strongly reduced interaction with CD80, CD86 and ICOSLG." evidence="31">
<original>E</original>
<variation>A</variation>
<variation>R</variation>
<location>
<position position="132"/>
</location>
</feature>
<feature type="mutagenesis site" description="Strongly reduced interaction with CD80, CD86 and ICOSLG." evidence="31">
<original>Y</original>
<variation>A</variation>
<variation>D</variation>
<location>
<position position="139"/>
</location>
</feature>
<feature type="mutagenesis site" description="Strongly reduced interaction with CD80, CD86 and ICOSLG." evidence="31">
<original>I</original>
<variation>A</variation>
<variation>D</variation>
<location>
<position position="143"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 3; ABG85285." ref="3" evidence="39">
<original>A</original>
<variation>V</variation>
<location>
<position position="37"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 8; AAA52773." ref="8" evidence="39">
<original>T</original>
<variation>A</variation>
<location>
<position position="147"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="39"/>
<end position="41"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="44"/>
<end position="47"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="50"/>
<end position="52"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="54"/>
<end position="60"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="64"/>
<end position="66"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="68"/>
<end position="77"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="80"/>
<end position="90"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="102"/>
<end position="108"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="111"/>
<end position="116"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="121"/>
<end position="123"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="125"/>
<end position="138"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="140"/>
<end position="143"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="147"/>
<end position="150"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="156"/>
<end position="158"/>
</location>
</feature>
<evidence key="1" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1AH1"/>
</source>
</evidence>
<evidence key="2" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1I85"/>
</source>
</evidence>
<evidence key="3" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1I8L"/>
</source>
</evidence>
<evidence key="4" type="ECO:0000244">
<source>
<dbReference type="PDB" id="3BX7"/>
</source>
</evidence>
<evidence key="5" type="ECO:0000244">
<source>
<dbReference type="PDB" id="3OSK"/>
</source>
</evidence>
<evidence key="6" type="ECO:0000244">
<source>
<dbReference type="PDB" id="5GGV"/>
</source>
</evidence>
<evidence key="7" type="ECO:0000244">
<source>
<dbReference type="PDB" id="5TRU"/>
</source>
</evidence>
<evidence key="8" type="ECO:0000255"/>
<evidence key="9" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10189842"/>
</source>
</evidence>
<evidence key="10" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10475192"/>
</source>
</evidence>
<evidence key="11" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10493833"/>
</source>
</evidence>
<evidence key="12" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10842319"/>
</source>
</evidence>
<evidence key="13" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10903931"/>
</source>
</evidence>
<evidence key="14" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10924276"/>
</source>
</evidence>
<evidence key="15" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11279501"/>
</source>
</evidence>
<evidence key="16" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11279502"/>
</source>
</evidence>
<evidence key="17" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12724780"/>
</source>
</evidence>
<evidence key="18" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15138458"/>
</source>
</evidence>
<evidence key="19" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15452244"/>
</source>
</evidence>
<evidence key="20" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15657618"/>
</source>
</evidence>
<evidence key="21" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15688186"/>
</source>
</evidence>
<evidence key="22" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16002699"/>
</source>
</evidence>
<evidence key="23" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16551244"/>
</source>
</evidence>
<evidence key="24" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="1713603"/>
</source>
</evidence>
<evidence key="25" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="1714933"/>
</source>
</evidence>
<evidence key="26" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18468488"/>
</source>
</evidence>
<evidence key="27" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18595775"/>
</source>
</evidence>
<evidence key="28" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21156796"/>
</source>
</evidence>
<evidence key="29" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="25213377"/>
</source>
</evidence>
<evidence key="30" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="25329329"/>
</source>
</evidence>
<evidence key="31" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="28484017"/>
</source>
</evidence>
<evidence key="32" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9175836"/>
</source>
</evidence>
<evidence key="33" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9228944"/>
</source>
</evidence>
<evidence key="34" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9259273"/>
</source>
</evidence>
<evidence key="35" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9813138"/>
</source>
</evidence>
<evidence key="36" type="ECO:0000269">
<source ref="23"/>
</evidence>
<evidence key="37" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="18595775"/>
</source>
</evidence>
<evidence key="38" type="ECO:0000303">
<source ref="9"/>
</evidence>
<evidence key="39" type="ECO:0000305"/>
<evidence key="40" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="28484017"/>
</source>
</evidence>
<sequence length="223" mass="24656" checksum="6F9466FB2E139A5A" modified="2003-01-10" version="3" precursor="true">MACLGFQRHKAQLNLATRTWPCTLLFFLLFIPVFCKAMHVAQPAVVLASSRGIASFVCEYASPGKATEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYLGIGNGTQIYVIDPEPCPDSDFLLWILAAVSSGLFFYSFLLTAVSLSKMLKKRSPLTTGVYVKMPPTEPECEKQFQPYFIPIN</sequence>
</entry>
<copyright>
Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
Distributed under the Creative Commons Attribution (CC BY 4.0) License
</copyright>
</uniprot>

